Condition: Advance Solid Tumors · Sponsor: Kivu Bioscience Inc.
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
This description comes directly from the study's public registry record.
Kivu Bioscience (US) · +1.650.606.5170 · KIVU10701@kivubioscience.com
Kivu Bioscience (Australia) · +61 8 7223 0122 · KIVU10701@kivubioscience.com
Always discuss trial participation with your own doctor first.
| Kivu Trial Site | Santa Monica, California, United States | Recruiting |
| Kivu Trial Site | Camperdown, New South Wales, Australia | Recruiting |
| Kivu Trial Site | Sydney, New South Wales, Australia | Recruiting |
| Kivu Trial Site | Brisbane, Queensland, Australia | Recruiting |
| Kivu Trial Site | Adelaide, South Australia, Australia | Recruiting |
| Kivu Trial Site | Geelong, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07229313